Bcl-2 anticorps (pSer87) (Biotin)

N° du produit ABIN1700450

L’anticorps Lapin Polyclonal anti-Bcl-2 a été validé pour ELISA, IHC (p) et IHC (fro). Il convient pour détecter Bcl-2 dans des échantillons de Humain et Rat.

Aperçu rapide pour Bcl-2 anticorps (pSer87) (Biotin) (ABIN1700450)

Antigène: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Reactivité: Humain, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Bcl-2 est conjugé à/à la Biotin

Application: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-Bcl-2 anticorps (Biotin)

Épitope: pSer87

Réactivité croisée: Humain, Rat

Homologie: Mouse,Horse,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic phosphopeptide derived from human Bcl2 around the phosphorylation site of Ser87

Isotype: IgG

Information d'application

Indications d'application: IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur Bcl-2

Antigène: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Autre désignation: Bcl2

Sujet:

Synonyms: Bcl2 phospho S87, Bcl2 phospho Ser87, p-Bcl2 phospho S87, p-Bcl2 Ser87, Apoptosis regulator Bcl 2, Apoptosis regulator Bcl2, AW986256, B cell CLL/lymphoma 2, B cell leukemia/lymphoma 2, B cell lymphoma 2, Bcl 2, Bcl-2, Bcl2, BCL2 protein, C430015F12Rik, D630044D05Rik, D830018M01Rik, Leukemia/lymphoma, B-cell, 2, Oncogene B-cell leukemia 2, BCL2_HUMAN, Apoptosis regulator Bcl-2.

Background: BCL2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants (alpha and beta) produced by alternate splicing, differ in their C-terminal ends. BCL2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability. It appears to function in a feedback loop system with caspases. BCL2 inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF1). It can form homodimers, and heterodimers with BAX, BAD, BAK and BclX(L). Heterodimerization with BAX requires intact BH1 and BH2 domains, and is necessary for anti-apoptotic activity. Also interacts with APAF1, RAF1, TP53BP2, BBC3, BCL2L1 and BNIPL.

ID gène: 596

Pathways: Signalisation MAPK, Signalisation PI3K-Akt, Apoptose, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling